There’s a mural on a brick wall in a buzzing Philadelphia coffee shop that said more than most launch readouts ever will.
Impatient Health’s annual gathering of pharma leaders who’d rather fix things than politely discuss them surfaced some unfiltered truths. The mural captured it as it was, brought to life by a muralist as the event unfolded. The visuals told more than a story – they exposed the assumptions and decision patterns the industry is still clinging to. A meteor streaks toward a pile of old playbooks. A launch leader, clutching her calendar, is hard-pressed to make timely decisions and drive outcomes. A KPI dashboard gets crossed out in red. And across the bottom, a poignant statement: “We need to stop asking permission… Asking assumes someone above you knows better.”
This wasn’t decoration. It was a diagnostic.
The Quiet Truths, Out Loud
What made Pharmageddon different wasn’t the format — though running a Deal or No Deal session with live launch scenarios in front of a room of senior pharma leaders is certainly not the standard conference playbook. What made it different was what people were willing to say.
Activity metrics are vanity metrics. Lance Hill, CEO of Within3, said it bluntly: “Benchmarks are easy to hit. And easier to hide behind.” They make leaders feel good – teams are busy. But so what? The real KPI? Evidence that behavior actually changed. Medical Affairs teams know this tension intimately. They can show slide after slide of engagement metrics and still have no idea whether a single treater shifted their approach. The industry has gotten remarkably good at measuring effort and remarkably bad at measuring impact.
Being right late is not good enough. One of the mural’s most evocative images: a woman in visible distress next to a tortured calendar. The message was clear — you can’t afford to be right late. Having the right information for decisions is important, but so is the timeliness of these actions. Leaders can’t afford to wait. Not when launch trajectories and success are set in the first six months, and rarely reverse course. Speed to action isn’t a nice-to-have. It’s the difference between a course correction and a post-mortem.
Drowning in data, starving for answers. This one showed up on the wall and in every hallway conversation. The problem isn’t access to information or insights — it’s that this wealth of data is rarely truly connected, let alone strategically anchored. Medical has sentiment data. Commercial has script data. Market access has coverage data. None of them tells the same story; yet all could be right in their own truths. But no one has time to reconcile it all before the next executive review. And guess what? Together they paint the true reality – it’s One launch, One product, One indication. If medical, commercial, or market access fails — everyone loses.
Stop asking permission. Perhaps the most provocative line on the wall — and the one that drew the most nods. The old model of waiting for consensus, escalating for approval, running it through one more committee — that model assumes someone higher up has better information. In most launch organizations, they don’t. They’re just further from the signal or looking at it from an entirely different angle.
Deal or No Deal: Three Launches, Three Moments of Truth
Continuing the tradition of breaking the mold, Lance was put in the hot seat for a game of Deal or No Deal. Spoiler alert: Lance nailed it.
Paul Simms, CEO of Impatient Health, walked Lance and the room through three launch scenarios — pre-launch, at-launch, and post-launch — each framed as a deal-or-no-deal decision.
Each scenario presented a pharma persona facing a real decision. Each got a “banker’s offer” — the conventional, defensible, nobody-gets-fired-for-choosing-it approach. And then Lance had to decide: Is that good enough?
The pre-launch scenario discussed Dr. Reyes, a Medical Affairs Strategist, who was challenged on whether she really knew who was shaping prescribing conversations in her disease area, or just who publishes the most. The at-launch scenario described Sarah, a Launch Strategist, on a Tuesday morning, where field signals and prescription data are diverging, and no one can say whether it’s noise or a trajectory-setting pattern. The post-launch scenario was of a VP of Commercial, Rachel, on the night before an executive review, trying to reconcile four dashboards into one answer to the CEO’s question: Are we winning?
In each case, the banker’s offer was reasonable. Structured. Defensible. Lance was asked to put himself in their shoes. And in each case, he said No Deal — because defensible isn’t the same as sufficient. As Lance put it during the session, nothing makes you feel quite so good but lets you see quite so little as a KPI dashboard. And as Paul Simms impressed in the room: do you actually know what you know — in time for it to matter?
The verdict across those scenarios was unanimous between Lance and the audience. The industry default — the triage calls, the commissioned studies, the consolidated dashboards — gets a No Deal. Not because it’s wrong, but because it’s slow. And in launch, slow is expensive.
The Wall Made the Reality Visceral
The mural didn’t simply tell the recap of the event, but was painted as the event happened, with quotes and impressions of what the room was saying in real time. So it brought these truths to light; the feeling was visceral. By the end of the day, the wall told a complete story: an industry that knows the old model is breaking, that can feel the gap between the data it collects and the decisions it needs to make, and that’s ready to stop waiting for someone else to go first.
One line on the mural put it simply: “Evolution doesn’t wait for consensus.”
Neither should your next launch.
Every Launch decision is consequential. The window to adapt is short.
You only launch once.
Go deeper with the Impatient Launch Leadership white paper — a closer look at why the industry’s launch model is overdue for reinvention, and what the leaders getting it right are doing differently.
